Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis.: Preliminary results in 24 patients

被引:74
|
作者
Elias, D
Sideris, L
Pocard, M
Edè, C
Ben Hassouna, D
Ducreux, M
Boige, V
Côté, JF
Lasser, P
机构
[1] Inst Gustave Roussy, Dept Surg Oncol, Villejuif, France
[2] Inst Gustave Roussy, Intens Care Unit, Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Inst Gustave Roussy, Dept Pathol, Villejuif, France
关键词
colorectal; intraperitoneal chemohyperthermia; oxaliplatin; peritoneal carcinomatosis; surgery;
D O I
10.1093/annonc/mdh186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease, leads to cure in some patients. We report preliminary results on survival in a phase II study using oxaliplatin (LOHP). Patients and methods: Twenty-four patients with macroscopic colorectal PC underwent complete resection of the PC followed by IPCH with LOHP performed in an open abdominal cavity. The dose of LOHP was 460 mg/m(2) in 21/m(2), during 30 min at 43degreesC, at a flow rate of 21/min. During the hour preceding IPCH, they received an intravenous administration of 5-fluorouracil (400 mg/m(2)) and leucovorin (20 mg/m(2)). Results: Mean peritoneal tumoral extension (Sugarbaker's Index) was 16.9 +/- 9.5, median operative duration was 490 min and median blood loss was 965 ml. There were two postoperative deaths (8%) by intracerebral hemorrhage, and morbidity rate was 41.6%. Minimal follow-up was 18 months and median follow-up was 27.4 months (range 18.3-49.6). At 1, 2 and 3 years, overall survival rates were 83%, 74% and 65%, and disease-free survival rates were 70%, 50% and 50%, respectively. Only 32% of the 22 postoperative living patients presented a peritoneal recurrence. A peritoneal index >24 influenced survival, with a 17% recurrence rate at 2 years versus 63% when it was <24 (P = 0.005). Conclusion: This new modality of treatment, when feasible, gives encouraging preliminary results, with a promising 3-year survival rate of 65%.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [41] Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin
    Perez-Ruixo, Carlos
    Valenzuela, Belen
    Esteban Peris, Jose
    Bretcha-Boix, Pedro
    Escudero-Ortiz, Vanesa
    Farre-Alegre, Jose
    Jose Perez-Ruixo, Juan
    CLINICAL PHARMACOKINETICS, 2013, 52 (12) : 1111 - 1125
  • [42] Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients
    Carlos Pérez-Ruixo
    José E. Peris
    Vanesa Escudero-Ortiz
    Pedro Bretcha-Boix
    José Farré-Alegre
    Juan José Pérez-Ruixo
    Belén Valenzuela
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1009 - 1020
  • [43] Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery
    Perez-Ruixo, Carlos
    Valenzuela, Belen
    Esteban Peris, Jose
    Bretcha-Boix, Pedro
    Escudero-Ortiz, Vanesa
    Farre-Alegre, Jose
    Jose Perez-Ruixo, Juan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 693 - 704
  • [44] Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin
    Carlos Pérez-Ruixo
    Belén Valenzuela
    José Esteban Peris
    Pedro Bretcha-Boix
    Vanesa Escudero-Ortiz
    José Farré-Alegre
    Juan José Pérez-Ruixo
    The AAPS Journal, 2016, 18 : 239 - 250
  • [45] Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin
    Carlos Pérez-Ruixo
    Belén Valenzuela
    José Esteban Peris
    Pedro Bretcha-Boix
    Vanesa Escudero-Ortiz
    José Farré-Alegre
    Juan José Pérez-Ruixo
    Clinical Pharmacokinetics, 2013, 52 : 1111 - 1125
  • [46] Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery
    Carlos Pérez-Ruixo
    Belén Valenzuela
    José Esteban Peris
    Pedro Bretcha-Boix
    Vanesa Escudero-Ortiz
    José Farré-Alegre
    Juan José Pérez-Ruixo
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 693 - 704
  • [47] Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin
    Perez-Ruixo, Carlos
    Valenzuela, Belen
    Esteban Peris, Jose
    Bretcha-Boix, Pedro
    Escudero-Ortiz, Vanesa
    Farre-Alegre, Jose
    Perez-Ruixo, Juan Jose
    AAPS JOURNAL, 2016, 18 (01): : 239 - 250
  • [48] Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients
    Perez-Ruixo, Carlos
    Peris, Jose E.
    Escudero-Ortiz, Vanesa
    Bretcha-Boix, Pedro
    Farre-Alegre, Jose
    Jose Perez-Ruixo, Juan
    Valenzuela, Belen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1009 - 1020
  • [49] Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin for Peritoneal Carcinomatosis Arising From Colorectal Cancer
    Gervais, Mai-Kim
    Dube, Pierre
    McConnell, Yarrow
    Drolet, Pierre
    Mitchell, Andrew
    Sideris, Lucas
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (07) : 438 - 443
  • [50] Autopsy of an expert consensus: End of hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis. Editorial
    Gomez Portilla, Alberto
    EJSO, 2019, 45 (09): : 1752 - 1753